Stimulants Uncovered: Separating Fact from Fiction on Addiction, Heart Health, and Methamphetamine Withdrawal

Key Takeaways

Takeaway	Details
Therapeutic stimulant medications do not increase addiction risk	Stimulant drugs, when properly prescribed for ADHD, reduce substance abuse, suicidality, criminal behavior, injury, and death. Longer and earlier treatment brings greater protection.
Untreated ADHD carries significant health and mortality risks	ADHD increases risk for heart disease, accidents, substance misuse, and early death. Medication lowers these risks and is an important public health measure.
Stimulant medications are cardiovascularly safe at the population level	Large-scale studies show no raised risk of cardiovascular disease in those using ADHD meds. Any effect on heart rate or blood pressure is mild and not clinically relevant.
ADHD not stimulant treatment is linked to higher cardiovascular risk	People with ADHD face increased cardiovascular risks even without medication. Treatment may reduce this risk by improving executive function and lowering impulsivity and injuries.
Formulation and route of administration matter for safety and misuse risk	Extended-release and prodrug forms (e.g., lisdexamfetamine) have lower abuse potential than immediate-release versions, especially when taken orally. Misuse is highest among those with conduct or substance issues.
Stimulants show emerging promise for methamphetamine withdrawal and dependence	Clinical trials suggest lisdexamfetamine may help treat methamphetamine dependence safely, though more evidence is needed.
Functional benefits extend well beyond symptom reduction	ADHD meds improve social, academic, and work functioning and quality of life, reducing disability and health burdens in the long term.
Women and neurodivergent populations face unique risks from delayed diagnosis	Women and neurodivergent people are often diagnosed late, increasing psychiatric and cardiovascular problems. Early, tailored treatment leads to better outcomes.
The overall risk–benefit profile strongly favors treatment	Serious side effects are rare and reversible. The benefits lower mortality, injury, and substance use outweigh risks for most people, making stimulant therapy safer than untreated ADHD.

Introduction

The Landscape of ADHD Pharmacotherapy

ADHD affects about 5.3%–7.1% of children and 4.4%–5.0% of adults worldwide. Contrary to earlier beliefs, roughly 65% of cases continue into adulthood, often with persistent symptoms that fluctuate in nearly 90% of adults. For over fifty years, stimulant medications like methylphenidate and amphetamines have been central in ADHD treatment, enhancing attention and behavioral control through increased neurotransmitter activity in the prefrontal cortex. Despite proven effectiveness, myths persist stimulants do not cause addiction, do not significantly raise cardiovascular risk, and have uses beyond ADHD, as supported by scientific evidence.

Why Myths Persist and Their Consequences

Misunderstandings about stimulant medications have real consequences for neurodivergent individuals, especially those with ADHD. Delayed diagnosis or lack of proper treatment leads to ongoing social, academic, and professional challenges, increased accident risk, premature mortality, and lower quality of life. The issue is pronounced among women and girls, who are often underdiagnosed in childhood; the diagnostic gap nearly disappears in adulthood. Many women report prolonged feelings of inadequacy before receiving an accurate diagnosis.

Understanding Stimulant Medications: Mechanisms of Action

Pharmacological Mechanisms

Stimulant medications for ADHD work mainly by blocking dopamine (DAT) and norepinephrine (NET) transporters, increasing these neurotransmitters in the synapse, and promoting their release. This primarily boosts activity in the prefrontal cortex, which is key for executive function and attention. Therapeutic oral use leads to gradual dopamine increases, supporting proper brain function, while recreational routes cause rapid dopamine spikes in reward pathways linked to addiction. Importantly, after three weeks of methylphenidate treatment, striatal DAT binding drops about 52%, regardless of substance use history. These differences explain why prescribed stimulants, taken orally, do not typically cause addiction-related brain changes.

Available Formulations

FDA-approved stimulant medications include amphetamine-based (Adderall) and methylphenidate-based (Ritalin/Concerta) products, which are offered as immediate-release (IR), sustained-release (SR), and extended-release (ER) formulations. Lisdexamfetamine (Vyvanse) is a prodrug that requires enzymatic conversion within the body to yield its active metabolite, d-amphetamine; this process mitigates abuse potential by delaying the onset of action. Extended-release preparations provide stable plasma concentrations for 8–12 hours, minimizing variability between peak and trough levels and promoting consistent medication adherence. Additionally, non-stimulant options such as atomoxetine, guanfacine extended-release, clonidine extended-release, and viloxazine extended-release are available for individuals who are unable to tolerate or adequately respond to stimulants.

Myth 1: Stimulant Medications Increase Addiction Risk

The Evidence Against Increased Addiction Risk

Contrary to common belief, research shows that prescribing stimulants for ADHD does not raise the risk of substance use disorders; rather, it may lower it. Large studies, such as Chang et al. (2013) in Sweden, found no increased risk and noted that longer stimulant treatment was linked to less substance abuse. A systematic review by Boland et al. (2020) found that ADHD medication offers robust protection against substance use disorders, mood disorders, suicidality, criminal behavior, injuries, and poor educational outcomes, especially during periods of adherence to medication.

Recent Longitudinal and Population-Based Evidence (2023–2025)

Recent studies confirm that ADHD medication is linked to lower all-cause, unnatural-cause, and suicide mortality. Li et al. (2024) found reduced deaths, including accidental poisoning, among 148,578 Swedish individuals with ADHD who began medication. Vasiliadis et al. (2024) observed, in a Quebec cohort of 217,192 aged 1–24, that medication use periods were associated with fewer deaths, unintentional injuries, and injury hospitalizations across both stimulant and non-stimulant types. Another Swedish study also reported a lower risk of suicide during stimulant prescription periods.

Quantified Effects: Study Comparison Table

Study	Year	Design	Sample Size	Key Finding	Effect Size
Chang et al.	2013	Population-based registry	Swedish national data	Longer medication duration → lower substance abuse	Protective trend
Boland et al.	2020	Meta-analysis (21 studies)	Multiple registries	Protective effect on SUDs, mood disorders, criminality	Robust across outcomes
McCabe et al.	2023	Longitudinal survey (MTF)	National US sample	Later initiation and shorter duration → higher illicit stimulant risk	Nuanced risk profile
Vasiliadis et al.	2024	Population-based cohort	217,192	Reduced mortality, injuries during medication use	aHR 0.61 mortality
Li et al.	2024	Target trial emulation	148,578	Lower all-cause and unnatural-cause mortality	HR 0.79 all-cause
Swedish register study	2023	Case-crossover	National data	Stimulants associated with decreased suicide mortality	OR 0.57

Nuances and Risk Factors for Misuse

Evidence suggests therapeutic stimulants protect against misuse, but details matter for clinical practice. McCabe et al. (2023) found later treatment initiation and shorter duration increase adolescents' risk of illicit or non-prescribed stimulant use; early, ongoing therapy is most protective. Chiappini et al. (2024) noted methylphenidate misuse is linked to impulsivity, substance abuse history, conduct disorder, immediate-release formulas, and non-oral administration, which heighten adverse outcomes like cardiovascular events and psychosis. A 10-year study showed all ADHD patients who diverted medication had conduct or substance use disorders and used immediate-release forms. These data underscore the need for extended-release prescriptions in high-risk cases, early treatment onset, and careful screening for comorbidities.

Limitations of the Addiction Risk Literature

Despite compelling evidence for a protective effect, several limitations should be acknowledged. Most large-scale studies rely on registry or administrative data, which may not capture non-prescription use, medication sharing, or detailed patterns of adherence. Residual confounding factors, including unmeasured lifestyle or engagement factors, cannot be fully excluded in observational designs. Randomized controlled trials directly testing the causal effect of stimulants on substance use disorder risk are not feasible due to ethical and practical constraints. Consequently, the evidence base relies on well-designed observational studies.

Myth 2: Stimulant Medications Cause Heart Disease

Foundational Evidence: JAMA Network Open Meta-Analysis

The comprehensive review of cardiovascular risk associated with ADHD stimulant medications comes from Zhang et al. (2022), published in JAMA Network Open. This systematic review and meta-analysis included 19 observational studies with more than 3.9 million participants. The key finding was that there is no statistically significant association between ADHD medications and risk of cardiovascular events in children, adolescents, or adults. This analysis is a landmark for clinicians, providing reassurance that routine ADHD pharmacotherapy does not elevate cardiovascular disease risk at the population level.

ADHD as an Independent Cardiovascular Risk Factor

ADHD, even without medication, increases the risk of cardiovascular disease. In a Swedish cohort study of over 5 million adults, 38.05% of those with ADHD were diagnosed with at least one cardiovascular condition versus 23.57% without ADHD. ADHD was linked to higher risks for cardiac arrest, hemorrhagic stroke, and peripheral vascular disease. While other risk factors reduced these associations, they did not fully account for them, indicating ADHD itself is an independent cardiovascular risk factor. This highlights untreated ADHD as a notable concern for heart health.

How Stimulant Medications Affect Blood Flow and Circulation

Stimulant medications cause mild, manageable increases in blood pressure and heart rate, especially with amphetamines, according to Nanda et al. (2023). No serious cardiovascular events were found in children or adolescents. Hennissen et al. (2017) reported that amphetamines and atomoxetine raised these parameters slightly, while methylphenidate did not. A 2025 review in The Lancet Psychiatry compared cardiovascular safety across ADHD medications, analyzing blood pressure, pulse, and ECG changes over multiple timepoints for a comprehensive assessment.

Recent Cardiovascular Safety Evidence (2023–2025)

Study	Year	Design	Sample Size	Key Finding	Effect Size
Zhang et al.	2022	Meta-analysis (19 studies)	>3.9 million	No significant CVD risk with ADHD meds	Non-significant across ages
Li et al.	2022	Population cohort	5,389,519	ADHD itself is independent CVD risk factor	HR 2.05 for any CVD
Nanda et al.	2023	Systematic review (13 studies)	Multiple cohorts	Small BP/HR increases; no serious CV events	Clinically manageable
Li et al.	2024	Target trial emulation	148,578	No increased natural-cause mortality	HR 0.86 (non-significant)
Vasiliadis et al.	2024	Population cohort	217,192	Stimulants reduce all-cause mortality	aHR 0.61
Cortese et al.	2025	Network meta-analysis (102 RCTs)	Multiple trials	Comparative CV safety across medications	Data at 12/26/52 weeks

Clinical Monitoring Recommendations

While overall population data is encouraging, clinical guidelines still stress close cardiovascular monitoring for each patient. This begins with an initial assessment covering blood pressure, heart rate, and both personal and family cardiac history. Blood pressure and pulse should be checked regularly during treatment, particularly when adjusting dosages. Electrocardiograms (ECGs) are only recommended if there's a relevant cardiac history, symptoms, or family history of sudden cardiac death. Patients with existing cardiovascular issues, obesity, or co-occurring eating disorders require more frequent monitoring. It's also important to note that untreated ADHD, especially alongside substance use or eating disorders, substantially heightens the risk of developing cardiovascular disease.

Limitations of Cardiovascular Evidence

Most cardiovascular safety data for stimulant medications are derived from observational studies or short- to medium-term randomized controlled trials. Very long-term outcomes from randomized studies are unavailable. The 2025 Lancet Psychiatry network meta-analysis assessed outcomes up to 52 weeks but could not address longer-term structural cardiovascular changes. Studies on cardiovascular safety in older adults (over 65 years) with ADHD are scarce, representing an important evidence gap as the number of adults diagnosed with ADHD continues to increase.

Myth 3: Stimulants Have No Role in Treating Methamphetamine Withdrawal

The Therapeutic Logic of Agonist Substitution

Agonist therapies use safer substances like drugs of abuse to treat addiction. Methadone and buprenorphine, for example, help manage opioid dependence by easing withdrawal and preventing relapse. Researchers are now examining whether lisdexamfetamine (LDX), a d-amphetamine prodrug, could have a similar effect for methamphetamine dependence.

Foundational Studies: Acheson et al. (2022) and Ezard et al. (2021)

Acheson et al. (2022) reported on an open-label pilot study of lisdexamfetamine for acute methamphetamine withdrawal, primarily assessing safety, tolerability, and feasibility, with secondary measures of withdrawal symptoms and craving. Similarly, Ezard et al. (2021) conducted a Phase 2 dose-escalation study in adults with methamphetamine dependence; 14 out of 16 participants reached 250 mg/day of LDX, and only two withdrew early. The findings indicate oral LDX up to 250 mg/day is safe and tolerable, supporting further efficacy research.

Breakthrough: The 2024 Randomized Controlled Trial

In December 2024, the journal Addiction published results from a randomized, double-blind, placebo-controlled trial of lisdexamfetamine for methamphetamine dependence, conducted at six specialist outpatient clinics in Australia. This study evaluated the efficacy and safety of a 12-week course of LDX for reducing methamphetamine use in individuals with dependence. Results showed that lisdexamfetamine reduced methamphetamine use over the 12-week treatment period, though the evidence for sustained reduction during the final four weeks of treatment was weak. Nausea was one of the most frequently reported adverse events, and serious adverse events occurred in 5% of participants receiving LDX.

Implications for Addiction Medicine

The emerging evidence for LDX marks a significant development in methamphetamine treatment, an area where no FDA-approved pharmacotherapy currently exists. The agonist substitution strategy with lisdexamfetamine offers several notable advantages:

Feature	Description
Controlled pharmacokinetics	As a prodrug requiring enzymatic activation, LDX possesses lower abuse potential compared to methamphetamine or immediate-release amphetamines.
Manageable safety profile	Evidence from both Phase 2 and randomized controlled trials demonstrates that LDX is tolerable, even at high doses (up to 250 mg/day) used in methamphetamine treatment.
Dual utility	For patients with comorbid ADHD and methamphetamine dependence—a frequently observed co-occurrence—LDX may be effective for both conditions.
Clinical feasibility	Oral administration in outpatient settings is more scalable and accessible than inpatient detoxification models.

Study Progression: Methamphetamine-Withdrawal Research

Study	Year	Design	Sample	Key Finding
Ezard et al.	2021	Phase 2 dose-escalation	16 adults with MA dependence	87.5% completed escalation to 250 mg/day; safe and tolerable.
Acheson et al.	2022	Open-label pilot protocol	Acute MA withdrawal	First study protocol for LDX in acute withdrawal.
LDX RCT (Addiction)	2024	Randomized double-blind placebo-controlled	Six outpatient clinics, Australia	LDX reduced methamphetamine use over 12 weeks.

Limitations of the Methamphetamine Evidence

Research on lisdexamfetamine (LDX) for methamphetamine dependence is still limited. Studies so far have had small groups and short follow-ups. A 2024 trial showed weak lasting effects, and long-term relapse data are missing. Past reviews, like Cochrane’s, reported no significant abstinence benefit with psychostimulants. Recent LDX data hint at some improvement, but large Phase 3 trials with longer follow-up are needed before routine clinical use can be recommended.

Beyond the Myths: Broader Efficacy and Functional Outcomes

Functional Improvements Beyond Symptom Reduction

The benefits of stimulant medications extend far beyond core ADHD symptom reduction. Kosheleff et al. (2023) conducted a narrative review in the Journal of Attention Disorders documenting that pharmacological treatment effectively minimizes not only ADHD symptoms but also functional consequences, including social impairment, relationship difficulties, professional underperformance, and quality of life deficits. Double-blind and open-label trials of methylphenidate demonstrated large, significant improvements in social functioning, with the proportion of participants scoring moderately impaired or worse dropping from 89% at baseline to 9% at six months of treatment.

Mortality Reduction: A Public Health Imperative

Mortality data strongly supports timely ADHD treatment. Li et al. (2024) found that starting ADHD medication reduced 2-year mortality by 8.9 deaths per 10,000 people. Since ADHD affects 5.9% of youth and 2.5% of adults globally, effective medication could have major public health benefits. The mortality risk with untreated ADHD is like type 2 diabetes. Vasiliadis et al. (2024) reported that stimulants, but not non-stimulants, were linked to significantly lower all-cause mortality difference possibly due to stimulants’ stronger and faster effects or prescribing patterns.

Considerations for Diverse Populations

Adults with ADHD

ADHD affects between 2.5% and 5.0% of adults, and its impact is now recognized as significant across the lifespan. The disorder is associated with substantial functional and health burdens well beyond childhood. Evidence indicates that pharmacological treatment in adults, particularly with methylphenidate and lisdexamfetamine, is as effective for symptom reduction and functional improvement as it is in pediatric populations.

Women and Gender Disparities

A systematic review by Attoe and Climie (2023) identified four primary challenges faced by adult women with ADHD: social-emotional wellbeing, relationship difficulties, lack of control, and the process of self-acceptance following diagnosis. Women diagnosed with ADHD in adulthood often encounter significant challenges in social-emotional functioning, including reduced self-esteem and difficulties in peer relationships. In the absence of early diagnosis, many women develop coping strategies that mask their symptoms but are at increased risk for psychiatric comorbidities such as depression, anxiety, and eating disorders. These additional disorders further worsen functional impairment and elevate cardiovascular risk.

Neurodivergent Populations

Effectively managing co-occurring neurodevelopmental disorders is essential, especially when conditions like ADHD occur alongside autism spectrum disorder. The risk of cardiovascular issues can vary according to an individual's specific neurodevelopmental profile. For instance, research by Li et al. (2022) found that people with both ADHD and autism spectrum disorder had a lower cardiovascular hazard ratio than those with ADHD paired with conduct disorder or substance use disorders. These findings highlight the importance of customizing treatment plans based on each patient’s unique neurodevelopmental features.

Adverse Effects: An Evidence-Based Assessment

Stimulant medications often used to treat ADHD can cause several side effects, as reported in medical studies. Although these side effects are common, they tend to be mild and can usually be handled with the right clinical approach.

Common and Manageable Effects

Common adverse effects include appetite suppression, weight loss, sleep disturbances, and mild gastrointestinal symptoms. Sleep issues are more frequent with late dosing but can be reduced by morning administration of extended-release forms. Stimulants may cause slight increases in blood pressure and heart rate, which are typically not clinically significant. In children, methylphenidate can slightly reduce height and weight gain temporarily, but these changes are not clinically impactful.

Effect	Details & Management
Appetite suppression and weight loss	Commonly observed, dose-related, generally manageable with nutritional counseling.
Sleep disturbance	More prevalent with later dosing; improved by extended-release morning administration.
Gastrointestinal symptoms	Includes abdominal pain and nausea; usually transient and mild.
Mild hemodynamic changes	Slight increases in blood pressure and heart rate; typically, not clinically significant.
Growth effects	Mild reductions in height and weight gain with methylphenidate; temporary and minimal in clinical impact.

Psychosis Risk

Although rare, new-onset psychosis has been documented with stimulant use. A large cohort study indicated that the overall incidence of stimulant-associated psychosis is approximately 1 in 660 patients. Amphetamines are associated with roughly twice the risk of psychosis compared to methylphenidate. These episodes are commonly resolved after discontinuing the medication.

Risk-Benefit Calculus

When considering the adverse effects alongside the benefits of stimulant therapy, including reductions in mortality, injuries, substance use disorder risk, and improvements in academic, occupational functioning, and quality of life, the risk-benefit profile for most individuals with ADHD is strongly favorable. Serious adverse events are rare, and the most common side effects can be managed with proper clinical monitoring.

Directions for Future Research

Although stimulant use is well-supported, further research is needed on long-term cardiovascular effects in both children and adults, especially as adult ADHD diagnoses rise. Large phase 3 lisdexamfetamine trials for methamphetamine dependence, with varied populations and extended follow-up, are necessary to evaluate relapse prevention. Sex-stratified analyses matter due to differences in mortality and comorbidities between males and females with ADHD. Older adults are rarely involved in pharmacotherapy studies and should be included. Future research should explore integrated treatments (combining stimulants with cognitive-behavioral therapy) and precision medicine strategies like pharmacogenomics.

Research Area	Focus
Long-term cardiovascular outcomes	Prospective studies in both children and adults are needed.
Phase 3 trials of lisdexamfetamine	Should include diverse populations and assess relapse prevention in methamphetamine dependence.
Sex-stratified analyses	Important for understanding differential efficacy and safety.
Studies in older adults	Over 65, a population underrepresented in trials.
Integrated treatment studies	Combining pharmacotherapy with cognitive-behavioral therapy for comorbid ADHD and substance use disorders.
Precision medicine approaches	Including pharmacogenomic predictors of stimulant response and adverse effects.

Conclusion

Comprehensive reviews encompassing meta-analyses, cohort studies, and randomized controlled trials indicate that, when prescribed and carefully monitored, therapeutic stimulant use does not elevate addiction risk or result in clinically significant cardiovascular disease. Furthermore, stimulants have demonstrated potential as treatment options for methamphetamine dependence. The risks associated with untreated ADHD, including increased likelihood of cardiovascular disease, premature mortality, substance use disorders, and pervasive functional impairment, considerably outweigh those linked to stimulant therapy. For neurodivergent individuals, it is imperative that evidence-based treatments are utilized to ensure equity, dignity, and optimal health outcomes.

Annotated Bibliography

1. Acheson, L. S., Ezard, N., Lintzeris, N., et al. (2022)

• This study protocol marks the first assessment of lisdexamfetamine (LDX) for acute methamphetamine withdrawal. It establishes important safety, tolerability, and feasibility parameters that will guide future efficacy trials. The protocol provides a foundation for understanding how LDX may be integrated into clinical practice for managing withdrawal symptoms.

2. Attoe, D. E., & Climie, E. A. (2023)

• Through a systematic review, this work highlights the significant effects of late ADHD diagnosis on adult women’s social-emotional wellbeing. The study documents pervasive impacts on relationships and self-acceptance, underscoring the importance of timely identification and intervention for this population.

3. Boland, H., DiSalvo, M., Fried, R., et al. (2020)

• This meta-analysis synthesizes findings from 40 studies, demonstrating that ADHD medication exerts robust protective effects across multiple domains. The medications significantly reduce the risk of mood disorders, suicidality, criminality, substance use disorders (SUDs), injuries, and support improved academic outcomes.

4. Chang, Z., Lichtenstein, P., Halldner, L., et al. (2013)

• Drawing on Swedish national register data, this population-based study reveals that longer durations of ADHD medication use are associated with lower rates of substance abuse. The findings reinforce the protective role of sustained pharmacological treatment in reducing substance misuse risk.

5. Chiappini, S., Gramuglia, P. D., Mosca, A., et al. (2024)

• This systematic review of 12 studies (N=1,551) identifies key risk factors for methylphenidate (MPH) misuse in individuals with psychiatric and substance use disorders. Impulsivity and conduct disorder are highlighted as significant contributors to misuse within this dual-diagnosis population.

6. Ezard, N., Clifford, B., Dunlop, A., et al. (2021)

• In this phase-2 dose-escalation study, 87.5% of participants with methamphetamine dependence completed escalation to 250 mg/day LDX. The study demonstrates acceptable tolerability and provides critical safety data to inform future trials and clinical guidelines.

7. Kosheleff, A. R., Mason, O., Jain, R., et al. (2023)

• Through a narrative review of 179 papers, this work documents widespread functional impairments among adults with untreated ADHD. It also presents evidence that pharmacotherapy mitigates deficits in social, professional, and quality-of-life areas, emphasizing the value of medical treatment for adult ADHD.

8. Li, L., Chang, Z., Sun, J., et al. (2022)

• This nationwide cohort study (N=5,389,519) from Sweden demonstrates that ADHD independently doubles the risk of cardiovascular disease (HR=2.05), regardless of medication use. The findings emphasize the importance of cardiovascular risk monitoring in individuals with ADHD.

9. Li, L., Zhu, N., Zhang, L., et al. (2024)

• A target trial emulation involving 148,578 participants shows that initiation of ADHD medication is associated with a 21% reduction in all-cause mortality (HR=0.79) and a 25% reduction in unnatural-cause mortality (HR=0.75), supporting the survival benefits of pharmacotherapy.

10. Lisdexamfetamine RCT for Methamphetamine Dependence (2024)

• This randomized, placebo-controlled trial conducted across six Australian clinics demonstrates that LDX reduces methamphetamine use over a 12-week period. The study provides evidence for the efficacy of LDX in supporting recovery from methamphetamine dependence.

11. Nanda, A., Janga, L. S. N., Sambe, H. G., et al. (2023)

• A comprehensive systematic review of 13 studies finds that ADHD stimulants produce manageable side effects, such as small increases in blood pressure and heart rate, with no serious cardiovascular events reported in children and adolescents.

12. Vasiliadis, H.-M., Lunghi, C., Rahme, E., et al. (2024)

• In this population-based cohort study (N=217,192), stimulant medication is associated with a 39% reduction in all-cause mortality (aHR=0.61) and a 25% reduction in injury-related emergency department visits (aHR=0.75), highlighting its protective effects.

13. Zhang, L., Yao, H., Li, L., et al. (2022)

• A systematic review and meta-analysis of 19 studies involving over 3.9 million participants finds no significant association between ADHD medications and increased cardiovascular disease risk, supporting their cardiovascular safety.

14. Cortese, S., et al. (2025)

• This network meta-analysis of 102 randomized controlled trials provides the most comprehensive comparative cardiovascular safety data for ADHD medications in children, adolescents, and adults, evaluated at 12, 26, and 52 weeks.

15. Stimulant Medication and Suicide Mortality in ADHD (2023)

• A Swedish register-based case-crossover study reports that stimulant prescription is associated with a 43% reduction in suicide mortality (OR=0.57), emphasizing the life-saving potential of stimulant medication for individuals with ADHD.